Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients (SILOAM)
Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring Acute Myocardial Infarction, Percutaneous coronary intervention
Eligibility Criteria
Inclusion Criteria: Acute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.
Exclusion Criteria:
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol
- Uncontrolled hypertension
- History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.
- Baseline hemogram with Hb<10g/dL or PLT count<100,000/μL
- Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel
- Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
- Pregnancy
Sites / Locations
- Korea University Guro Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Dual antiplatelet therapy for 1 year
Triple antiplatelet therapy for 1 month
Triple antiplatelet therapy for 6 months
Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol